Söndag 27 April | 10:48:19 Europe / Stockholm

Prenumeration

2025-04-24 13:39:00

Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annual growth rate of 54% for 2020–2024 in the opioid use disorder market, a still strong outlook and a blockbuster pipeline.

Read more and download the Research Report.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/